CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,120 enrolled
Drug / intervention
Nepafenac Ophthalmic Suspension, 0.3% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01109173
NCT01109173Phase 3Completed
CompareCT.gov

Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery

Alcon Research·interventional·Posted Apr 23, 2010·Updated Nov 30, 2012

In Brief

A Phase 3 clinical trial evaluating Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, and 2 other interventions for Cataract. Completed, enrolled 2,120 participants across 1 site.

Detailed Summary

The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 23, 2010
Enrollment StartJun 1, 2010
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.2 years ago

Interventions

Nepafenac Ophthalmic Suspension, 0.3%drug

Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.

Nepafenac Ophthalmic Suspension, 0.1%drug

Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days

Nepafenac Ophthalmic Suspension 0.3% Vehicleother

Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.

NEVANAC Vehicleother

Nepafenac vehicle, one drop in affected eye three times daily, for 16 days